Bristol-Myers Squibb Company (NYSE: BMY) today announced positive results from a randomized Phase 2 study evaluating ipilimumab in combination with standard chemotherapy in previously untreated patients with advanced non-small cell lung cancer (NSCLC). The study, known as 041, met the predefined criteria for significant improvement (p-value of
Recent Posts
- Better Understanding Of Body's Response To Fasting May Lead To Therapies For Metabolic Disorders
- Fraud Discovery Institute Retracts Herbalife Accusations - California
- Dangers Of Doctors' Shorthand And Bad Writing - Diabetes UK
- Proposed Changes To Civil Claims Funding Will Be Fairer For All Says MDU
- Actelion Pharmaceuticals Announces FDA Approval Of Brand Name For Commercially Available VELETRI® (epoprostenol For Injection)
- Mayo Clinic First In U.S. To Use Newly-Approved FDA Technology To Treat Atrial Fibrillation
- New Jersey Health Department Orders Closure Of Abortion Clinic, Lawsuit Filed
- UCLA's Heart Transplant Program Ranked Best In The U.S.
- FDA Classifies Voluntary Notification Related To SC Catheters And IsoMed Pump Incompatibility As Class I Recall
- VELCADE Induction Followed By VELCADE Maintenance Improves Clinical Outcomes In Previously Untreated Multiple Myeloma Patients
- New Insurance Plans: Good News For People Diagnosed With Cancer